5-aminosalicylic acid inhibits cell cycle progression in a phospholipase D dependent manner in colorectal cancer
โ Scribed by Baan, B.; Dihal, A. A.; Hoff, E.; Bos, C. L.; Voorneveld, P. W.; Koelink, P. J.; Wildenberg, M. E.; Muncan, V.; Heijmans, J.; Verspaget, H. W.; Richel, D. J.; Hardwick, J. C. H.; Hommes, D. W.; Peppelenbosch, M. P.; van den Brink, G. R.
- Book ID
- 121833923
- Publisher
- BMJ Publishing Group
- Year
- 2011
- Tongue
- English
- Weight
- 921 KB
- Volume
- 61
- Category
- Article
- ISSN
- 0017-5749
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Introduction: Epidemiological data suggests that 5-aminosalicylic acid (5-asa), a nonsteroidal antiinflammatory drug used in the treatment of inflammatory bowel diseases, prevents colorectal cancer development in these patients, although the mechanisms remain incompletely understood. ## Methods
A roundtable consensus meeting was held to consolidate current knowledge on the etiology of colorectal cancer in patients with inflammatory bowel disease and to review current strategies, both diagnostic and preventive, specifically addressing the role of 5-aminosalicylic acid. Specific topics that